SuperworthDesign Therapeutics EPS DSGN
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$1.18
- Latest quarter, Q2 FY26
- −$0.32
- Fiscal year 2025
- −$1.22
Design Therapeutics' earnings per share was −$1.18 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.32.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.22 | n/a |
| FY2024 | −$0.88 | n/a |
| FY2023 | −$1.20 | n/a |
| FY2022 | −$1.14 | n/a |
| FY2021 | −$0.86 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.32 | n/a | −$1.18 | |
| Q1 FY26 | −$0.29 | n/a | −$1.20 | |
| Q4 FY25 | −$0.27 | n/a | −$1.22 | |
| Q3 FY25 | −$0.30 | n/a | −$1.19 | |
| Q2 FY25 | −$0.34 | n/a | −$1.12 | |
| Q1 FY25 | −$0.31 | n/a | −$0.99 | |
| Q4 FY24 | −$0.24 | n/a | −$0.88 | |
| Q3 FY24 | −$0.23 | n/a | −$0.85 | |
| Q2 FY24 | −$0.21 | n/a | −$0.90 | |
| Q1 FY24 | −$0.20 | n/a | −$1.05 | |
| Q4 FY23 | −$0.21 | n/a | −$1.20 | |
| Q3 FY23 | −$0.28 | n/a | −$1.30 |
Against its peers
Companies in Drug Manufacturers - General nearest Design Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| DSGNDesign Therapeutics | −$1.18 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| ARVNArvinas | $0.16 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| PCRXPacira BioSciences | $0.35 | |
| Peer median | $0.85 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Design Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.